- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03477604
A Clinical Evaluation of the MicroSTent® PeripherAl Vascular SteNt in Subjects With Arterial Disease Below the Knee (STAND)
October 3, 2022 updated by: Micro Medical Solution, Inc.
Randomized multicenter clinical trial consisting of two arms; one arm treated with PTA plus the MicroStent® System and one arm treated with PTA alone.
Purpose to evaluate the safety and effectiveness of using the MicroStent® Peripheral Vascular Stent System, hereafter referred to as the MicroStent® System, for the treatment of infrapopliteal lesions in subjects with peripheral arterial disease.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
177
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Kate Mandall
- Phone Number: 949-292-5466
- Email: kmandall@micromedicalsolutions.net
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35243
- Recruiting
- Cardiovascular Associates of the Southeast
-
Contact:
- Tammy Stover
- Email: tstover@cvapc.com
-
Principal Investigator:
- Jan Skowronski, MD
-
-
Arizona
-
Mesa, Arizona, United States, 85203
- Recruiting
- Modern Vascular
-
Contact:
- Denisse Martinez Gaspar
- Email: dmartinez@modernvascular.com
-
Principal Investigator:
- Scott Brannan, MD
-
-
California
-
Saint Helena, California, United States, 94574
- Recruiting
- St. Helena Hospital
-
Contact:
- Sue Sherman
- Email: Shermasr@ah.org
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Active, not recruiting
- Rocky Mountain Regional VA Medical Center
-
-
Florida
-
Fort Lauderdale, Florida, United States, 33312
- Recruiting
- Palm Vascular
-
Principal Investigator:
- Robert Beasley, MD
-
Jacksonville, Florida, United States, 32256
- Recruiting
- First Coast Cardiovascular Institute
-
Contact:
- Mary Hudson
- Phone Number: 1049 904-493-3333
- Email: mhudson@firstcoastcardio.com
-
Principal Investigator:
- Vaquar Ali, MD
-
Leesburg, Florida, United States, 34748
- Recruiting
- FHV Health
-
Contact:
- Shayna Rabess
- Email: shayna.rabess@fhvhealth.com
-
Principal Investigator:
- David Lew, MD
-
Miami Beach, Florida, United States, 33140
- Active, not recruiting
- Mount Sinai Medical Center
-
Sebring, Florida, United States, 33872
- Active, not recruiting
- Advent Health Sebring
-
-
Iowa
-
Davenport, Iowa, United States, 52807
- Recruiting
- Vascular Institute of the Midwest
-
Contact:
- Lynn Jarrett
- Phone Number: 563-324-3818
- Email: lynn.jarrett@vimidwest.com
-
Principal Investigator:
- Eric Dippel, MD
-
-
Louisiana
-
Houma, Louisiana, United States, 70360
- Recruiting
- Cardiovascular Institute of the South
-
Contact:
- Deanna Benoit
- Email: Deanna.Benoit@cardio.com
-
Principal Investigator:
- Craig Walker, MD
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- Recruiting
- University of Maryland - Baltimore
-
Contact:
- Shannon Hawkins
- Email: skiddoo@som.umaryland.edu
-
Principal Investigator:
- Khanjan Nagarsheth, MD
-
-
Michigan
-
Grand Rapids, Michigan, United States, 49525
- Recruiting
- Advanced Cardiac and Vascular Amputation Prevention Centers
-
Contact:
- Abigail Mize
- Email: amize@acvcenters.com
-
Principal Investigator:
- Fadi Saab, MD
-
Roseville, Michigan, United States, 48066
- Active, not recruiting
- Eastlake Cardiovascular
-
-
New Jersey
-
Browns Mills, New Jersey, United States, 08015
- Active, not recruiting
- Deborah Heart and Lung Center
-
Clifton, New Jersey, United States, 07013
- Active, not recruiting
- North Jersey Vascular Center
-
Galloway, New Jersey, United States, 08205
- Recruiting
- AMI Vascular Institute
-
Contact:
- Melisa Rivera
- Email: mrivera@aminj.com
-
Principal Investigator:
- Nicholas Petruzzi, MD
-
-
North Carolina
-
Raleigh, North Carolina, United States, 27607
- Withdrawn
- NC Heart and Vascular Research
-
-
Pennsylvania
-
Jefferson Hills, Pennsylvania, United States, 15025
- Recruiting
- US Cardiovascular
-
Contact:
- Lori DeGore
- Email: ldegore@pittvascular.com
-
Principal Investigator:
- Gennady Geskin, MD
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02904
- Recruiting
- Brown University
-
Principal Investigator:
- Peter Soukas, MD
-
-
South Carolina
-
Spartanburg, South Carolina, United States, 29303
- Recruiting
- Cardiology Consultants
-
Contact:
- Darla Howard
- Email: dhoward@srhs.com
-
Principal Investigator:
- Brian Brown, MD
-
-
Texas
-
Austin, Texas, United States, 78756
- Recruiting
- Cardiothoracic and Vascular Surgeons
-
Contact:
- Emily Rowe
- Email: erowe@ctvstexas.com
-
Principal Investigator:
- David Nation, MD
-
Tyler, Texas, United States, 75701
- Withdrawn
- Cardiovascular Associates of East Texas
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53221
- Recruiting
- AZH/WAVE Vascular Center
-
Contact:
- Becky Kastern, MD
- Email: bkastern@azhcenters.com
-
Principal Investigator:
- Awais Siddique, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
General Inclusion Criteria:
- Subject is a male or a non-pregnant female adult between the age of 21 and 90 years old.
- Subject has documented clinical evidence of critical limb ischemia (CLI) in the target limb prior to the index procedure, with a Rutherford Classification score of 4-5.
- The subject, or subject's designated legal representative, has been informed of the nature of the study and is willing to provide written informed consent.
- Subject is willing to comply with all required follow-up visits.
Subject life expectancy is ≥1 year per the Principal Investigator.
Angiographic Inclusion Criteria
- Target vessel reconstitutes at or above the ankle with inline flow to at least one patent (<50% stenosis) inframalleolar outflow vessel.
- Subject has a lesion, with ≥ 70% stenosis and ≤ 12.0 cm in length located at or distal to the tibial-peroneal trunk and above the tibiotalar joint; including the anterior tibial, posterior tibial or peroneal arteries.
- Target lesion has a reference vessel diameter of 2.5 - 4.5 mm
- The target lesion is able to be crossed with a guidewire to facilitate treatment with the randomized device.
General Exclusion Criteria:
- Subject had a prior or has a planned index limb amputation above the ankle.
- Subject has a wound/ulcer on the forefoot with a surface area >4cm² or osteomyelitis involving the calcaneus bone.
- Subject is pregnant, plans to become pregnant, or is nursing.
- Subject has clinical conditions that severely inhibit X-ray or duplex ultrasound visualization (e.g. body habitus).
- Subject has a history of hypercoagulation/clotting disorders or acute thrombosis.
- Subject has allergy to iodinated contrast media that cannot be adequately managed with medication.
- Subject is in acute renal failure.
- Subject has an active systemic infection.
- Subject is participating in another research study involving an investigational device, biologic, or drug that has not completed the primary endpoint at the time of randomization/enrollment.
- Subject has other comorbidities that - in the opinion of the investigator - preclude them from receiving study treatment and/or from completing the required study follow-up assessments.
- Subject presents with acute limb ischemia or acute thrombosis of the target limb.
- Subject has experienced myocardial infarction, thrombolysis, or angina less than 30 days prior to the index procedure.
Subject had a stroke within 3 months of index procedure.
Angiographic exclusion criteria
- Failure to successfully treat clinically significant inflow lesions in the ipsilateral iliac, femoral, or popliteal arteries. Successful treatment is defined as obtaining ≤30% residual stenosis with no major procedural complications (e.g embolism).
- Failure to successfully treat significant non-target infra-popliteal lesions. Successful treatment is defined as obtaining ≤30% residual stenosis with no major procedural complications (e.g. embolism).
- Target lesion is within a previously placed stent.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MicroStent and Standard PTA
Implant of the MicroStent peripheral vascular stent system for treatment of arterial lesions below the knee.
|
Self-expanding stent and standard PTA balloon
|
Active Comparator: Standard PTA
|
Standard PTA balloon
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patency of the target lesion
Time Frame: up to 6 months after randomization
|
Primary patency defined as freedom from target lesion occlusion with no clinically driven target lesion reintervention, or major amputation.
|
up to 6 months after randomization
|
Freedom from perioperative death
Time Frame: up to 30 days after randomization
|
Freedom from perioperative death
|
up to 30 days after randomization
|
Freedom from major adverse limb event
Time Frame: up to 6 months after randomization
|
Freedom from major adverse limb event
|
up to 6 months after randomization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Freedom from major amputation above the ankle
Time Frame: up to 6 months after randomization
|
Freedom from major amputation (above the ankle)
|
up to 6 months after randomization
|
Reduction in size of ischemic leg/foot ulcers
Time Frame: up to 6 months after randomization
|
Reduction in size of ischemic leg/foot ulcers
|
up to 6 months after randomization
|
Freedom from major adverse limb event
Time Frame: From date of randomization until the date of death from any cause assessed up to 36 months
|
Freedom from major adverse limb event
|
From date of randomization until the date of death from any cause assessed up to 36 months
|
Frequency and severity of serious adverse events and device and procedure related adverse events
Time Frame: From date of randomization until the date of death from any cause assessed up to 36 months
|
Frequency and severity of serious adverse events and device and procedure-related adverse events at any time during the study.
|
From date of randomization until the date of death from any cause assessed up to 36 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 19, 2019
Primary Completion (Anticipated)
July 1, 2023
Study Completion (Anticipated)
July 1, 2026
Study Registration Dates
First Submitted
March 8, 2018
First Submitted That Met QC Criteria
March 19, 2018
First Posted (Actual)
March 26, 2018
Study Record Updates
Last Update Posted (Actual)
October 4, 2022
Last Update Submitted That Met QC Criteria
October 3, 2022
Last Verified
October 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MMS-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral Arterial Disease
-
University of NebraskaNot yet recruitingPeripheral Arterial Disease | Peripheral Vascular Diseases | Peripheral Arterial Occlusive Disease | Peripheral Artery DiseaseUnited States
-
CID S.p.A.Meditrial Europe Ltd.Not yet recruitingPeripheral Arterial Occlusive Disease | Peripheral Artery DiseaseItaly
-
Marissa JarosinskiRecruitingPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery Disease | Clopidogrel, Poor Metabolism of | Artery DiseaseUnited States
-
Stanford UniversityTerminatedPAD - Peripheral Arterial Disease | PVD- Peripheral Vascular DiseaseUnited States
-
Vascuros Medical Pte LtdNovella ClinicalUnknownPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery DiseaseSingapore, Belgium, Germany
-
Western Vascular Institute, IrelandRecruitingPeripheral Arterial Occlusive DiseaseIreland
-
Jena University HospitalAngioDroid s.r.l., Bologna (Italy)CompletedPeripheral Arterial Occlusive DiseaseGermany
-
Seoul National University HospitalAstellas Pharma Korea, Inc.CompletedPeripheral Arterial Occlusive DiseaseKorea, Republic of
-
Heidelberg UniversityTerminatedPeripheral Arterial Occlusive DiseaseGermany
-
Johann Wolfgang Goethe University HospitalSuspendedPeripheral Arterial Occlusive DiseaseGermany
Clinical Trials on MicroStent and Standard PTA
-
TriReme Medical, LLCUniversity Hospitals Cleveland Medical CenterWithdrawnInfrainguinal Peripheral Arterial DiseaseUnited States
-
Neuromed IRCCSUnknown
-
Medtronic EndovascularCompletedCritical Lower Limb IschemiaGermany, Belgium, Netherlands, Switzerland, Austria, Italy
-
C. R. BardCompletedRestenosis | StenosisAustralia, Germany, Austria, United States, Belgium, New Zealand, Netherlands, Switzerland
-
Biotronik AGCompletedArteriosclerosis | Atherosclerosis | Peripheral Artery Disease | Vascular DiseaseBelgium, Austria, Germany
-
Boston Scientific CorporationActive, not recruitingCritical Limb IschemiaUnited States, France, Japan, Belgium, Netherlands
-
University of Maryland, BaltimoreCompleted
-
C. R. BardCompletedArteriovenous FistulaUnited States
-
Asian Eye InstituteIvantis, Inc.CompletedPrimary Angle Closure Glaucoma | Primary Angle ClosurePhilippines
-
Biotronik AGCompletedArteriosclerosis | Atherosclerosis | Peripheral Artery Disease | Vascular DiseaseGermany, Austria